$HIMS · The Motley Fool · 2026-11-10
HIMS是一个好坏参半的判断:季度增长跃升至49%,部分来自收购,估值倍数相对合理,每用户收入从两个季度前的80美元升至105美元;但利润率持续下滑,随着营销收缩,用户数减少约10万至279万,同时竞争加剧、模式依赖营销。一种看法是它太难、已放弃;另一种看法是在10年视角下近期噪音无关紧要,并看好其计划中的美国产肽类产品。
播放时,YouTube 可能接收设备与播放信息并使用 Cookie。 隐私说明 · Google 隐私政策
逐段跳播
Hims and Hers 过去一个月下跌了约 40%。他们是转向 AI 云了吗?还是说,对,他们需要,他们需要做那个 Allirds 转型。对,那大概应该,他们正在招聘大量 AI 人员。
只是还没在他们的产品里看到这一点。不过他们今天大幅下跌,截至我们录制时大约跌了 18%。
him and hers down about 40% in the past month. Did they pivot to uh AI cloud or Yeah, they need to Yeah, they need to do the uh the Allirds pivot. Yeah, that should probably They're hiring a lot of AI people. um just haven't seen that in in their products yet.
Uh but big move down for them today about 18% as we're recording right now.
这份财报真的很有意思,因为每个人都能从中找到点东西,如果你是 Nvidia 的多头,或者你是 Hims and Hers 的多头。你可以眯着眼把数字看得挺漂亮。我就展示几样我认为投资者会感兴趣的东西。
增长率。确认一下这些是季度数据。对,这些是季度数字。所以增长率跳到了 49%。有意思的一点是,我一直喜欢从市场得出的结论,股价大幅下跌,但你实际上看到增长率大幅跳升。这在一定程度上是因为收购。
他们收购了 Eucalyptus,收购了 Zava。Eucalyptus 会是这里最大的增量,但这对一家估值倍数相对合理的公司来说,增长率相当不错了。
The earnings report was really interesting because there's a little something for everybody if you are an Nvidia or if you're a hims and hers bull. You can, you know, squint and make the numbers look pretty good.
I'll just show uh show a couple of things that I think investors are going to be interested in. The growth rates. Make sure these are quarterly. Yep. These are quarterly numbers.
So, the growth rate jumps to 49%. So, one of the interesting I I I always like the takeaway from the market, you know, the stock's down significantly, but you're actually seeing the growth rate jump pretty significantly.
Now, this is partly because of acquisitions. They bought Eucalyptus, they bought uh Zava. Eucalyptus is going to be the big addition right here, but you know, that's a that's a pretty darn good growth rate for a company that's trading for a relatively reasonable multiple.
如果你是投资者,可能更让你担心的是利润率持续下降。这里有几个前提,我把屏幕藏一下,把数据调出来,但这家公司有一些有趣的动态,尤其是他们的营销方式。他们在电话会上说,最近一个季度他们实际上削减了一部分营销支出,把它推迟到年初。
年初之后,通常就是人们想“嘿,也许我今年想减点重”的时候。那时健身房会员数会跳升。我认为也是他们看到很多 GP1 产品销量跳升的时候。到那时市场上还会有肽类产品。他们预计本月晚些时候推出。
然后是 TRT。所以你有各种各样的产品,他们基本上是在说,我们把营销收回来,是为了把一切安排妥当,确保这些新产品能真正顺利开局。他们还和 Novo Nordisk 有另一个合作,或者说另一个产品。
Eli Lily 的产品之前就在他们的平台上,但这次是更好的合作,你实际上是直接从 Hims and Hers 拿到产品。
Um, what you may be a little bit more worried about if you are an investor is the fact that margins continue to go down. Now, couple of couple of caveats here and I'll I'll hide my screen just a second as I pull this up, but there is some interesting dynamics with this company specifically with the way that they're going to market.
So they said in their conference call that they are they actually pulled back on the some of their marketing spending in the most recent quarter to kind of hold that off to until the first of the year.
So after the first of the year typically when people go hey you know maybe I want to lose a little bit of weight this year. Uh that's when gym memberships jump. It's also when I think they see a lot of their GP1 in particular sales jump.
Um we're also going to have peptides in the market at that point. They're expecting to launch that later this month. And then TRT, too. So, you've got kind of a wide range of products and they're kind of saying, you know what, we pulled back in our marketing because we want to kind of get our ducks in a row and make sure that we're really hitting the ground running with these new products.
Uh they've also got another partnership with or another product coming from Novo Nordisk. Eli Lily's products just ended up they were on their platform before, but it's a little bit it's like a nicer partnership uh where you're actually getting it from him and hers.
还有一件事,连我都觉得有点意外。本季度订阅用户数下降了约 10 万。所以一个季度前是 289 万,最近这个季度是 279 万。这是一门用户流失率相对较高的生意。所以你停掉那台营销机器,订阅用户数就会下降。
但抵消这一点的是每用户收入的巨大跃升。现在是每月 105 美元。就在两个季度前还是 80 美元。所以涨了 20 美元。你在这里看到的是,记住 GLP1 类药物在配制的时候是相对便宜的产品。
我记得通过 Hims and Hers 是每月 150 美元,算是他们最低的价格点。那吸引了很多客户。然后他们现在几乎完全转向销售品牌产品。品牌产品的运作方式是,我会认为品牌产品本身的利润率相当低。
不是零,但接近零。所以你买的,比如说,一支 Ompic 笔或 Zepbound 之类的,你为它付的利润率很低,但在此之上,你还要付他们所谓的会员费。有点像 Costco 模式。
Costco 在你买的,比如说,花生酱上赚不了多少钱。他们靠会员费赚钱。利润就来自那里。这就是那个类比。所以你在数字里看到了这一点。他们在营销上花得更少。这意味着新客户进来得更少,但他们现有的客户价格点高得多,因为他们在转向这种会员模式,但利润率也更低。所以有很多不同的变量。
Here's the other thing that uh was a little bit surprising even to me. Um the number of subscribers dropped about 100,000 in the quarter. So 2.89 million a quarter ago, 2.79 million in this most recent quarter.
So this is going to be, you know, this is a relatively high churn business. So you you end that marketing machine and you're going to see the subscriber numbers go down. But offsetting that is a massive jump in revenue per subscriber.
Now $105 per month. Just two quarters ago that was $80. So a $20 increase. This is what you're seeing here is remember GLP1's when they were compounding those it was a relatively inexpensive product.
I think it was $150 a month uh through Hims and Hers was kind of their lowest price point. That got a lot of customers. Then they have they have now transitioned almost entirely to selling branded products.
And the way that the branded products works is, you know, I would I would think that the the margin on the actual branded product itself is pretty pretty low. Like not zero, but close to zero.
So you're buying, let's say, a, you know, Ompic pen or Zepbound or whatever it is. You're paying very little margin for that, but then on top of that, you're paying for what they call a membership.
A little bit like a Costco model. Like Costco makes very little money on the, you know, peanut butter that you buy at Costco. They make money on the membership. That's where their profit comes from.
So that's kind of the analogy there. So you're seeing this in the numbers. They're spending less on marketing. It means less new customers are coming in, but the customers that they have are a much higher price point because they're transitioning to this membership model, but they're also lower margin. So, a lot of different moving parts.
我们再看吧,这个领域太有意思了,因为竞争越来越激烈,但进入下一件事时我们再看。Andrew Hub,Huber,Huberman 加入董事会并担任顾问。所以他也会是我们经常看到的大人物。
但不管怎样,把这些加在一起,市场不喜欢它看到的东西。
Um, and we'll see, you know, it's it's such an interesting space because it is getting more competitive, but we'll see as we go into the the other thing. Andrew Hub Huber Huberman joining the board of directors and an adviser.
So, he's going to be a big name that we're going to see a lot, too. But anyways, add this all up and the market doesn't like what it sees.
我是说,从播客主的角度看,据我读到的,他拿到了一笔非常好的交易。所以,对,我记得是每年 700 万美元担任顾问,25 万美元的股权,再加上担任董事的一点象征性费用。所以,这是一笔不小的钱。
I mean, on the podcaster side of things, from what I read, he got a very good deal. So, yeah, I think it's like $7 million a year for being an adviser, $250,000 in equity, plus a nominal fee for being on the board of directors. So, yeah, it's it's a nice chunk of change.
对,一点也不差。从生意角度看,这仍然是一门增长中的生意,但对我来说,我一直觉得这是一门如果他们要营销,就必须大力营销才能继续增长、抢占更多市场份额的生意,而且这个行业里有预算比他们大得多的巨头。
当然,如果你继续发展自己的生态系统和会员基础,并确保流失率不上升、实际上还下降,那我想这是个不错的位置,但我只是把它归入对我来说太难的一类,所以跳过了。
Yeah, it's not not bad at all. Um, from the business standpoint, I mean, it's still a growing business, but I to me I always felt like this is a business where if they have to market, they have to market the business aggressively in order to continue to grow and to grab more market share and and it's an industry where you have giants that just have way larger budgets than them.
Now, of course, if you continue to grow your own ecosystem and your member base, then and make sure that churn doesn't go up, actually goes down, then I guess that that's that's a good position, but I've just put it in a two too difficult bucket for me, so skipped it.
还有一点我想提一下。营收在增长,虽然从百分比看毛利率在下降,但绝对毛利额是在上升的。所以再补充一点:如果你在看 HIMS 和 Hers 这两家,情况并不是全都糟糕,但我完全理解市场的反应——"等等,订阅用户数在下降。
这些数字本该是向上向右增长的。看起来竞争多了很多。现在利润率又更低了。"这是我一直反复说的那类公司之一:如果你以10年的视角看这家公司,这些都只是噪音,你要关注的是管理层在做什么。
我喜欢他们做的一些事情,我的意思是,我认为他们将成为唯一一家100%在美国生产肽类产品的公司。比如他们说自己在为 BPC57 之类的产品自产 API。如果你想进入这个领域,这大概是最有信誉的地方。
Here's the other thing that I just want to note. um revenue is going up at a level where even the fact even though the the gross margin from a percentage standpoint is going down, the absolute gross margin is going up.
So just another little note if you're looking at him and hers, it's not all terrible, but I definitely understand the market's reaction going, "Wait a second, subscriber numbers are down.
These are supposed to be going up and to the right. It looks like there's a lot more competition. Now you got lower margins." Um, you know, this is one of those companies that I keep saying over and over again.
If you if you have a 10-year view on the company, this is just noise and you want to listen to what management's doing. I like some of the stuff that they I mean, they're going to be, I think, the only place that's going to make peptides 100% in the US.
Like, they said that they're making their own APIs for BPC57 and things like that. Like, if you want to get into that stuff, this is probably the most reputable place to do it.
7%。没能完全抵消我 HIMS 持仓的亏损,但帮上了一点点。
7%. Not quite offsetting my HIMS position, but helping just a little.
我觉得,在我的投资组合里,今天这波走势之后,Zeta 会跃升到我的第一大持仓,而 HIMS 则会回落。我不知道是掉到第二还是第三,但没错,这是个不错的季度,事情继续朝着正确的方向发展。
I think, you know, in my portfolio, I think after this move today, Zeta jumps up to the number one position in my portfolio and now HIMS falls back down. I don't know if it's down to two or three, but uh, but yeah, good good quarter and things are continue to move in the right direction.
这个频道对 $HIMS 的历次判断
The Motley Fool 在这只股票上共 4 条判断,这里只列相邻的几条。